Tag: Edwards Lifesciences

First implant of Pascal transcatheter mitral valve repair device performed in...

The first implant of the Pascal mitral valve repair device (Edwards Lifesciences) in the CLASP IID pivotal trial has been performed at the Atlantic...

Launch of Sapien 3 Ultra hampered by Boston Scientific dispute

The CE mark has been granted to the Sapien 3 Ultra (Edwards Lifesciences) transcatheter aortic valve implantation (TAVI) device, but a dispute between Edwards...

US trial of Edwards’ self-expanding Centera valve begins

Edwards Lifesciences has commenced the US pivotal trial that will study its self-expanding Centera transcatheter aortic valve implantation (TAVI) device for severe, symptomatic aortic...

Boston Scientific successfully opposes Edwards Lifesciences Corporation’s European patent EP 2,399,550...

According to a press release, Boston Scientific has, along with several other opponents, successfully opposed Edwards Lifesciences Corporation's European patent EP 2,399,550 (550) in...

Enrolment complete in CT imaging substudy of leaflet mobility with Sapien...

Edwards Lifesciences has announced that enrolment is complete in the computed tomography (CT) imaging substudy within the PARTNER 3 trial of the Sapien 3...

UK Court of Appeal dismisses Edwards Lifesciences’ appeal against Sapien 3...

Acurate neo Boston Scientific has announced the UK Court of Appeal  dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’...

Edwards’ self-expanding Centera TAVI valve now on European market

Edwards Lifesciences has received the CE mark for its self-expanding Centera transcatheter aortic valve implantation (TAVI) valve for severe, symptomatic aortic stenosis patients at...
Edwards Lifesciences acquires Harpoon Medical

Harpoon Medical acquired by Edwards

Edwards Lifesciences Corporation today announced it has acquired Harpoon Medical, Inc., following its investment in the company in 2015. Edwards has paid US$100 million...

TCT 2017: TMVI in mitral ring is a reasonable alternative for...

Data from the MITRAL (Mitral Implantation of Transcatheter valves) study indicate that transeptal transcatheter mitral valve implantation (TMVI), with a Sapien 3 device (Edwards...

Edwards Lifesciences’ Alterra adaptive prestent device used for first time to...

Evan Zahn (Guerin Family Congenital Heart Program, Cedars-Sinai Heart Institute, Los Angeles, USA) has become the first interventional cardiologist to implant the Alterra adaptive...

FDA approve “first-in-class” resilient surgical valve

Edwards Lifesciences has FDA approval for its Inspiris Resilia surgical aortic valve, which a press release reports is the first in a new class...

German court awards Edwards Lifesciences co-entitlement of Neovasc’s Tiara patent application

The District Court in Munich, Germany has partially found in favour of Edwards Lifesciences Corporation (formerly CardiAQ Valve Technologies) in its case against Neovasc.  In...

First procedures using Edward Lifesciences’ Inspiris Resilia aortic valve take place

The first ever Inspiris Resilia aortic valve (Edwards Lifesciences) implantation procedures have successfully taken place in two UK hospitals—King’s College and Royal Brompton and...

EuroPCR 2017: Excellent early outcomes for Edwards Lifesciences’ self-expanding valve

According to late-breaking trial presented at EuroPCR (16–19 May, Paris, France), a novel self-expanding transcatheter aortic valve implantation device (TAVI, Centera, Edward Lifesciences) is...

ACC 2017: Embol-X and CardioGard do not reduce number of brain...

Two US Food and Drug Administration-cleared medical devices designed to remove potential vessel-blocking debris particles from the bloodstream during aortic valve replacement—EmbolX (Edwards LifeSciences)...

Edwards Lifesciences halts enrolment in Cardiaq trial

According to a SeekingAlpha transcript of an Edwards Lifesciences fourth-quarter 2016 earnings conference call, the company has put a halt on enrolment in its...

Edwards Lifesciences completes acquisition of Valtech Cardio

Edwards Lifesciences has closed its previously announced acquisition of Valtech Cardio, developer of the Cardioband system for transcatheter repair of the mitral and tricuspid...

Edward Lifesciences to acquire Valtech

Valtech Cardio has agreed to be acquired by Edwards Lifesciences. The acquisition will give Edwards access to Valtech’s Cardioband reconstruction system (Cardioband) for transcatheter...

TCT 2016: Transfemoral TAVI improves quality of life in intermediate-risk patients

Data presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Washington, DC, USA) indicate that intermediate-risk patients who undergo transcatheter aortic...

London Valves 2016: Edwards announces SAPIEN 3™ valve CE Mark approved...

PCR London Valves 2016 opened in the main arena with the Edwards Lifesciences TNT session "TAVI in 2016: the year the treatment of aortic...

New “resilient” surgical aortic valve now available in Europe

Edwards Lifesciences has received the CE mark for its Inspiris Resilia aortic valve, which is the first in a new class of resilient heart...

Sapien 3 now approved for intermediate-risk patients in Europe as well...

Following last month’s FDA approval for the expanded indication of Sapien 3 for the treatment of intermediate-risk patients with aortic stenosis, the device can...

FDA approval for Edwards Intuity Elite rapid deployment valve

Edwards Lifesciences has received FDA approval for its advanced Intuity Elite rapid deployment valve for surgical aortic valve replacement. A press release reports that...

Edwards Sapien 3 granted expanded indication from US FDA

Edwards Lifesciences has announced US Food and Drug Administration (FDA) approval to expand use of the Edwards Sapien 3 transcatheter heart valve for the...